Business

AGM and IMS

AGM and IMS.

articleHikma Pharmaceuticals PlcMay 15, 20083/company/hikma-pharmaceuticals-plc/news/agm-and-ims-1
AGM and IMS

About this update from Hikma Pharmaceuticals Plc

[{"type":"text","content":"\n RNS Number : 5258U Hikma Pharmaceuticals Plc 15 May 2008  \n \n\nAGM and Interim Management Statement\n\n\nLondon, 15 May 2008 - Hikma Pharmaceuticals PLC ('Hikma') (LSE:HIK)(DIFX:HIK), the fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products, will hold its AGM at 11:00am today, where the following statement will be made regarding its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 January 2008 to 14 May 2008 as required by the UK Listing Authority's Disclosure and Transparency Rules. \n\nIn the four months to 30 April 2008, Group sales grew by over 35%.  The Branded and Injectables businesses have continued to drive growth in the Group and we remain confident of delivering another year of strong performance in 2008.\n\nOur Branded business continues to deliver strong organic growth in line with our expectations, with further growth coming from our acquisitions in the MENA region.  This has helped us to achieve market share gains in many of our key markets. Hikma Egypt and APM in Jordan have been successfully integrated and we have made the expected productivity and process improvements. Both of these acquisitions are performing well.  \n\nOur global Injectables business has delivered strong revenue growth in the year to date.  Like others we are experiencing an increase in pricing pressure in the German market, but we remain confident of delivering improved operating margins for the full year.  We have made excellent progress in expanding our US product portfolio, with 4 ANDA approvals year to date, and in Europe and the MENA region we have received a further 6 and 10 approvals, respectively. As the year progresses, we expect further growth as we launch these new products across the Injectables business.\n\nAs anticipated at the time of our pr...

More updates from Hikma Pharmaceuticals Plc